2-(m-tolyl)benzo[d]isothiazol-3(2H)-one | 2514-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-(m-tolyl)benzo[d]isothiazol-3(2H)-one
• 英文别名: 2-(m-Tolyl)-1,2-benzothiazol-3-one；2-(3-methylphenyl)-1,2-benzothiazol-3-one
• CAS: 2514-31-0
• 化学式: C₁₄H₁₁NOS
• 分子量: 241.313
• InChiKey: OPKPVFLDKSVLMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(m-tolyl)benzo[d]isothiazol-3(2H)-one 在 双氧水 、 溶剂黄146 作用下， 反应 1.0h， 生成 1,1-dioxo-2-m-tolyl-1,2-dihydro-1λ⁶-benzo[d]isothiazol-3-one
  参考文献：
  名称：

  Gialdi,F. et al., Farmaco, Edizione Scientifica, 1961, vol. 16, p. 509 - 526

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(m-Tolyl)-2-mercapto-benzamid 在 四丁基溴化铵 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以82%的产率得到2-(m-tolyl)benzo[d]isothiazol-3(2H)-one
  参考文献：
  名称：

  通过脱氢 NS 键形成电化学合成苯并异噻唑-3(2H)-酮

  摘要：

  在此，我们报告了一种从 2-巯基苯甲酰胺合成苯并异噻唑-3(2H)-酮的电化学方法。电化学反应通过分子内 N H/S H 偶联环化反应进行，生成 H 2作为无害副产物。此外，该方法反应时间短，条件温和，底物范围广，无需使用金属催化剂和外源性氧化剂。2009 Elsevier Ltd. 版权所有。

  DOI：

  10.1016/j.tetlet.2021.153323

文献信息

• Co-Catalyzed Intramolecular S-N Bond Formation in Water for 1,2-Benzisothiazol-3(<i>2H</i> )-ones and 1,2,4-Thiadiazoles Synthesis
  作者：Liting Yang、Lijuan Song、Shanyu Tang、Longjia Li、Heng Li、Bingxin Yuan、Guanyu Yang

  DOI：10.1002/ejoc.201801642

  日期：2019.2.14

  Sustainable synthesis of 1,2‐benzisothiazol‐3(2H)‐ones and 1,2,4‐thiadiazoles via intramolecular S‐N bond formation were realized in aqueous media with good to excellent yields, which used tetra‐sulfonated cobalt phthalocyanine as a catalyst and molecular oxygen as the environment friendly oxidant.

  在水介质中以良好或优异的产率实现了通过分子内S-N键形成可持续合成1,2-苯并噻唑-3（2H）-one和1,2,4-噻二唑的方法，该方法使用四磺化钴酞菁钴催化剂和分子氧作为环境友好型氧化剂。
• Ligand-free access to benzisothiazolones and benzisoselenazolones through NiFe₂O₄ catalyzed concomitant annulation of 2-halobenzanilides with chalcogens and their late-stage transformations
  作者：Samiran Dhara、Moumita Saha、Asish R. Das

  DOI：10.1039/d2nj04326b

  日期：——

  temperature and useful application of synthesized molecules. The rarely explored chemistry of NiFe2O4 towards the X–N cross-coupling reaction well complements conventional methods for the synthesis of S–N or Se–N heterocycles. Nickel ferrite nanoparticles were prepared by a simple hydrothermal method and characterized by using XRD, SEM, TEM, HRTEM, SAED, energy dispersive X-ray spectroscopy, XPS, ICP-AES and

  本工作展示了一种有效的无配体合成多种苯并异噻唑酮和苯并异硒唑酮的方法，该方法利用 X-N（X = S，SE）交叉偶联中的磁性可回收纳米镍铁氧体催化剂与 2-碘苯苯胺和元素硫或硒的同时环化. 该协议的特点是使用可回收的纳米镍铁氧体催化剂、底物多样性、廉价的硫和硒粉作为硫属化物试剂、较低的反应温度和合成分子的有用应用。NiFe 2 O 4的罕见化学X-N 交叉偶联反应很好地补充了合成 S-N 或 SE-N 杂环的常规方法。采用简单的水热法制备了镍铁氧体纳米粒子，并通过XRD、SEM、TEM、HRTEM、SAED、能量色散X射线光谱、XPS、ICP-AES和FT-IR分析对其进行了表征。催化剂易于回收和产品转化率高，使该协议具有实际经济性。使用 TBN 和氧气作为正确的氧化剂组合，苯并异噻唑酮中易氧化的硫转化为各种糖精基序。此外，含 S-N 和 SE-N 的杂环都被放大并进一步转化为新的 C-H
• Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1
  作者：Yalda Bravo、Peter Teriete、Raveendra-Panickar Dhanya、Russell Dahl、Pooi San Lee、Tina Kiffer-Moreira、Santhi Reddy Ganji、Eduard Sergienko、Layton H. Smith、Colin Farquharson、José Luis Millán、Nicholas D.P. Cosford

  DOI：10.1016/j.bmcl.2014.07.013

  日期：2014.9

  We report the discovery and characterization of a series of benzoisothiazolone inhibitors of PHOSPHO1, a newly identified soluble phosphatase implicated in skeletal mineralization and soft tissue ossification abnormalities. High-throughput screening (HTS) of a small molecule library led to the identification of benzoisothiazolones as potent and selective inhibitors of PHOSPHO1. Critical structural requirements for activity were determined, and the compounds were subsequently derivatized and measured for in vitro activity and ADME parameters including metabolic stability and permeability. On the basis of its overall profile the benzoisothiazolone analogue 2q was selected as MLPCN probe ML086.
• FISCHER; HURNI, Arzneimittel-Forschung/Drug Research, 1964, vol. 14, p. 1301 - 1306
  作者：FISCHER、HURNI

  DOI：——

  日期：——
• Potent, Selective, and Orally Available Benzoisothiazolone Phosphomannose Isomerase Inhibitors as Probes for Congenital Disorder of Glycosylation Ia
  作者：Russell Dahl、Yalda Bravo、Vandana Sharma、Mie Ichikawa、Raveendra-Panickar Dhanya、Michael Hedrick、Brock Brown、Justin Rascon、Michael Vicchiarelli、Arianna Mangravita-Novo、Li Yang、Derek Stonich、Ying Su、Layton H. Smith、Eduard Sergienko、Hudson H. Freeze、Nicholas D. P. Cosford

  DOI：10.1021/jm101401a

  日期：2011.5.26

  We report the discovery and validation of a series of benzoisothiazolones as potent inhibitors of phosphomannose isomerase (PM), an enzyme that converts mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) and, more importantly, competes with phosphomannomutase 2 (PMM2) for Man-6-P, diverting this substrate from critical protein glycosylation events. In congenital disorder of glycosylation type Ia, PMM2 activity is compromised.; thus, PMI inhibition is a potential strategy for the development of therapeutics. High-throughput screening (HTS) and subsequent chemical optimization led to the identification of a novel class of benzoisothiazolones as potent PMI inhibitors having little or no PMM2 inhibition. Two complementary synthetic routes were developed, enabling the critical structural requirements for activity to be determined, and the compounds were subsequently profiled in biochemical and cellular assays to assess efficacy. The most promising compounds were also profiled for bioavailability parameters, including metabolic stability, plasma stability, and permeability. The pharmacokinetic profile of a representative of this series (compound 19; ML089) was also assessed, demonstrating the potential of this series for in vivo efficacy when dosed orally in disease models.